Lack of Efficacy of Streptozocin and Doxorubicin in Patients With Advanced Pancreatic Endocrine Tumors
Andrea M. McCollum(Centers for Disease Control and Prevention), Charles S. Fuchs(University of Southern California), Matthew H. Kulke(Moffitt Cancer Center), Robert J. Mayer(Applied Natural Sciences), David P. Ryan(East Carolina University), Lawrence N. Shulman(National Center for Health Research), Jeffrey W. Clark(Massachusetts General Hospital), Sylvia Bartel(Dana-Farber Cancer Institute)
Cited by 123
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k